Theragen has announced that it has been granted a US patent for the development of its ActaStim-S spine fusion bone growth stimulator system.
ActaStim-S blends clinically proven therapeutic stimulation with modern design and a data-rich digital health platform, says Theragen. The system not only promotes healing, it encourages patient compliance, engagement, and informed dialogue with healthcare providers during the critical — and lengthy — post-operative fusion process, the company adds.
Chris McAuliffe, co-inventor and Theragen CEO, said: “Spinal fusion is a healing process, often characterised as a race to achieve solid fusion before failure of the implanted hardware. Electrical stimulation is a clinically proven, safe and effective postoperative adjunct therapy that can help patients win that race, however its clinical effectiveness requires regular use over several months.
“That’s why we’ve taken a user-centric approach, designing a more wearable device that also offers a digital health component that gives patients the unique opportunity to engage in, follow, and truly impact their own recovery.”
Fellow co-inventor, Richard Pearce, who is also the firm’s COO and vice president of research and development, added: “The system includes a remarkably discreet, unobtrusive wearable unit that is very well received by patients. It includes utilisation tracking, on-board activity sensing, Bluetooth smartphone connectivity, and an intuitive app that helps patients visualise their progress over time.
“The essence of this new US patent is focused on ensuring that this connectivity does not interfere with ease of use—and that data collection and transfer can happen quickly and effectively.”